Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: A nested substudy of the MAP.3 randomised controlled trial

The Lancet Oncology

Volumn 13, Issue 3, 2012, Pages 275-284

  Cheung, Angela M ^a   Tile, Lianne ^a   Cardew, Savannah ^a   Pruthi, Sandhya ^d   Robbins, John ^f   Tomlinson, George ^a   Kapral, Moira K ^a   Khosla, Sundeep ^c   Majumdar, Sharmila ^e   Erlandson, Marta ^a   Scher, Judy ^a   Hu, Hanxian ^a   Demaras, Alice ^a   Lickley, Lavina ^b   Bordeleau, Louise ^g   Elser, Christine ^b   Ingle, James ^d   Richardson, Harriet ^h   Goss, Paul E ⁱ  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Endocrine Research Unit   (United States)

^d MAYO CLINIC ROCHESTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h QUEEN S UNIVERSITY   (Canada)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; EXEMESTANE; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BREAST CANCER; CONTROLLED STUDY; CORTICAL BONE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; METABOLIC BONE DISEASE; MULTICENTER STUDY; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ABSORPTIOMETRY, PHOTON; ANDROSTADIENES; ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; BONE AND BONES; BONE DENSITY; BREAST NEOPLASMS; CALCIUM; CANADA; CHI-SQUARE DISTRIBUTION; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS; PATIENT SELECTION; PLACEBOS; POSTMENOPAUSE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES; VITAMIN D;

EID: 84857502692     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70389-8     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA: Cancer J Clin 2011, 61:69-90.
2. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141.
3. Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011, 12:1109-1117.
4. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med 2004, 350:1081-1092.
5. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Eng J Med 2011, 364:2381-2391.
6. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clinl Oncol 2008, 26:1051-1057.
7. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
8. Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009, 20:1489-1498.
9. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 2005, 97:1652-1662.
10. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996, 14:78-84.
11. McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007, 43:2523-2531.
12. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007, 9:R52.
13. Goss P, Grynpas MD, Qi S, Hu H The effects of exemestane on bone and lipids in the ovariectomized rat. Breast Cancer Res Treat 2001, 69:224.
14. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004, 10:5717-5723.
15. Hung A, Hamidi M, Riazantseva E, et al. Validation of a calcium assessment tool in postmenopausal Canadian women. Maturitas 2011, 69:168-172.
16. Cheung AM, Detsky AS Osteoporosis and fractures: missing the bridge?. JAMA 2008, 299:1468-1470.
17. Seeman E, Delmas PD Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
18. Fan B, Lu Y, Genant H, Fuerst T, Shepherd J Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems?. Osteopor Int 2010, 21:1227-1236.
19. Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994, 9:1503-1514.
20. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteopor Int 2008, 19:1395-1408.
21. D'Agostino RB, Massaro JM, Sullivan LM Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat Med 2003, 22:169-186.
22. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010, 25:1886-1894.
23. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230). J Bone Miner Res 2006, 21:1215-1223.
24. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635.
25. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clinl Oncol 2005, 23:5126-5137.
26. Slatkovska L, Alibhai SM, Beyene J, Hu H, Demaras A, Cheung AM Effect of 12 months of whole-body vibration therapy on bone density and structure in postmenopausal women: a randomized trial. Ann Intern Med 2011, 155:668-679.
27. Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.
28. Khosla S, Melton LJ, Riggs BL The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. J Bone Miner Res 2011, 26:441-451.
29. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119-127.
30. Riggs BL, Melton LJ, Robb RA, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 2004, 19:1945-1954.
31. Vanderschueren D, Venken K, Ophoff J, Bouillon R, Boonen S Sex steroids and the periosteum-reconsidering the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab 2006, 91:378-382.
32. Jones S, Stokoe C, Sborov M, et al. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Clin Breast Cancer 2008, 8:527-532.
33. Hadji P, Asmar L, van Nes JG, et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clinl Oncol 2011, 137:1015-1025.
34. Cigler T, Richardson H, Yaffe M, et al. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat 2011, 126:453-461.
35. Singh S, Cuzick J, Blake GM, et al. One year effect of anastrozole and risedronate on bone mineral density: first results from the IBIS-II bone sub-study. Bone 2011, 48:S24.
36. Vico L, Zouch M, Amirouche A, et al. High-resolution pQCT analysis at the distal radius and tibia discriminates patients with recent wrist and femoral neck fractures. J Bone Miner Res 2008, 23:1741-1750.
37. Kazakia GJ, Burghardt AJ, Link TM, Majumdar S Variations in morphological and biomechanical indices at the distal radius in subjects with identical BMD. J Biomech 2011, 44:257-266.
38. Stein EM, Liu XS, Nickolas TL, et al. Abnormal microarchitecture and reduced stiffness at the radius and tibia in postmenopausal women with fractures. J Bone Miner Res 2010, 25:2572-2581.
39. Sornay-Rendu E, Boutroy SP, Munoz F, Delmas PD Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY Study. J Bone Miner Res 2007, 22:425-433.
40. Varga P, Pahr DH, Baumbach S, Zysset PK HR-pQCT based FE analysis of the most distal radius section provides an improved prediction of Colles' fracture load in vitro. Bone 2010, 47:982-988.
41. Nishiyama K, Macdonald H, Hanley DA, Boyd SK. Bone microarchitecture and finite element analysis measured with HRpQCT can identify postmenopausal women with and without forearm fragility fractures. American Society of Bone Mineral Research Annual Meeting; San Diego, CA, USA, Sept 16-20, 2011. Abstract SU0037.
42. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004, 34:736-746.
43. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
44. Coleman RE, Banks LM, Girgis SI, et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 2010, 124:153-161.